Choroideremia associated with choroidal neovascularization treated with intravitreal bevacizumab

• Published in: Clinical ophthalmology (Auckland, N.Z.) N.Z.), 2014-09, Vol.8 (default), p.1675-1679
• Main Authors: Palejwala, Neal V, Lauer, Andreas K, Weleber, Richard G
• Format: Article
• Language: English
• Subjects: Acuity; Anatomy; anti-VEGF therapy; Atrophy; Case Report; Case studies; chorioretinal degeneration; choroidal neovascular membrane; Choroideremia; Diagnosis; Diagnostic systems; Drug therapy; Edema; Eye examinations; Fibrosis; Growth factors; hereditary choroidal dystrophy; Immunotherapy; intravitreal bevacizumab injection; Males; Monoclonal antibodies; Ophthalmology; Patients; Photoreceptors; Retina; Therapy; Tomography; Vascular endothelial growth factor
• ISSN: 1177-5467; 1177-5483; 1177-5483
• DOI: 10.2147/OPTH.S68243

To report a rare case of central vision loss in a patient with choroideremia. A retrospective, interventional case report. A 13-year-old male with history of choroideremia presented with subacute loss of central acuity in his left eye. Examination and diagnostic testing revealed subretinal fibrosis secondary to a choroidal neovascular membrane (CNVM). A trial of anti-vascular endothelial growth factor (VEGF) therapy with the injection of intravitreal bevacizumab was attempted. Mild improvements in acuity and anatomy were noted. Choroideremia is a rare hereditary choroidal dystrophy that predominantly affects males in the first and second decades of life. Visual acuity is usually spared until later in life. CNVM is a rare manifestation of choroideremia with only a handful of case reports presented in the literature. This case is unique in that it is the first reported case that received treatment with intravitreal anti-VEGF therapy.